Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968958 | 0.76 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3SLC6A9 | |
| SCHEMBL24967970 | 0.76 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3SLC6A9 | |
| SCHEMBL26088929 | 0.74 | CHRM4 (0.53) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL20555984 | 0.73 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL28646033 | 0.73 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL23744764 | 0.73 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL14636960 | 0.73 | CCNE2 (0.51) | CHRM2CHRM1SLC6A9 | |
| SCHEMBL14650212 | 0.73 | SLC6A9 (0.39) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL15858041 | 0.72 | GAA (0.53) | CHRM2CHRM1CXCR3 | |
| SCHEMBL27765593 | 0.72 | GAA (0.53) | CHRM2CHRM1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | CHRM2 1/4885CHRM1 3/4885CHRM4 2/4885 |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885CHRM1 1/4885CHRM4 3/4885 |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM2, CHRM1, CHRM4 | CHRM2 1/4885CHRM1 2/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.